Half-year report · HY
2531.TEDINET S100X1G2
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥186.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥362.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥176.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥7.8bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥10.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥7.4bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.2bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥8.6bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥13.7bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥16.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥9.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥476.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥477.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥447.8bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥189.2bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥176.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥287.5bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥300.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥296.5bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥60.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥83.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥54.0bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥75.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥89.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.2bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥18.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥41.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥29.4 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.98 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.55 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 49.8% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.3% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥15.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥7.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥8.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥1.7bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥9.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥9.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥702m |
| Takara Bio Groupreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥103.9bn |
| Takara Bio Groupreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥103.7bn |
| Takara Bio Groupreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥177m |
| Takara Bio Groupreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥6.7bn |
| Takara Healthcarereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥18.8bn |
| Takara Healthcarereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥18.8bn |
| Takara Healthcarereportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Takara Healthcarereportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥2.3bn |
| Takara Shuzo Groupreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥57.8bn |
| Takara Shuzo Groupreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥57.1bn |
| Takara Shuzo Groupreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥679m |
| Takara Shuzo Groupreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥180.4bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥179.6bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥857m |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥6.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥196.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥186.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥9.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥8.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥15.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥6.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥8.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥9.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥9.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥395m |
| Takara Bio Groupreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥89.0bn |
| Takara Bio Groupreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥88.8bn |
| Takara Bio Groupreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥227m |
| Takara Bio Groupreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥6.5bn |
| Takara Healthcarereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥19.8bn |
| Takara Healthcarereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥19.8bn |
| Takara Healthcarereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Takara Healthcarereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥417m |
| Takara Shuzo Groupreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥62.0bn |
| Takara Shuzo Groupreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| Takara Shuzo Groupreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥504m |
| Takara Shuzo Groupreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥170.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥170.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥732m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥9.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥186.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥176.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥10.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 517
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1InterimDuration | － | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | InterimDuration | -6416000000 | JPY |
| Other net inv cf | Prior1InterimDuration | -316000000 | JPY |
| Other net inv cf | InterimDuration | -533000000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | -2313000000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | -18352000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1InterimDuration | -12000000 | JPY |
| Net increase decrease in short term loans payable fin cf | InterimDuration | -768000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1InterimDuration | 100000000 | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration | 9951000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -5163000000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -5394000000 | JPY |
| Redemption of bonds fin cf | Prior1InterimDuration | -5000000000 | JPY |
| Redemption of bonds fin cf | InterimDuration | － | JPY |
| Proceeds from issuance of commercial papers fin cf | Prior1InterimDuration | 8000000000 | JPY |
| Proceeds from issuance of commercial papers fin cf | InterimDuration | － | JPY |
| Purchase of treasury stock fin cf | Prior1InterimDuration | -0 | JPY |
| Purchase of treasury stock fin cf | InterimDuration | -2999000000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -5654000000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -6050000000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1InterimDuration | -813000000 | JPY |
| Dividends paid to non controlling interests fin cf | InterimDuration | -891000000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration | -591000000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration | -633000000 | JPY |
| Other net fin cf | Prior1InterimDuration | -1000000 | JPY |
| Other net fin cf | InterimDuration | -6000000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -9136000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -6794000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | 4986000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | -2112000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -255000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -21290000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 90184000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 75280000000 | JPY |
| Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries cce | Prior1InterimDuration | － | JPY |
| Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries cce | InterimDuration | 49000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 89929000000 | JPY |
| Cash and cash equivalents | InterimInstant | 54039000000 | JPY |
| Employees salaries and bonuses sga | Prior1InterimDuration | 13627000000 | JPY |
| Employees salaries and bonuses sga | InterimDuration | 15384000000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 2108000000 | JPY |
| Provision for bonuses sga | InterimDuration | 2007000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraShuzoGroupReportableSegmentsMember | 61475000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraBioGroupReportableSegmentsMember | 88752000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00396-000TakaraHealthcareReportableSegmentsMember | 19757000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 169985000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 6554000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 176539000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 176539000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |